Privately-held NormOxys Raises $17.5 Million Series B To Further Develop Its Novel "Oxyren" Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The money, provided by returning backer Index Ventures and new investor Care Capital, will support clinical development of NormOxys' lead drug candidate through proof-of-concept testing.